Sign Up for a Free Account
  • Updated 03.31.2021
  • Released 05.17.2000
  • Expires For CME 03.31.2024



Historical note and terminology

One of the earliest approaches for Alzheimer disease treatment was augmentation of cholinergic activity, which was based on a loss of acetylcholine in the frontal cortex and the hippocampus. Physostigmine, 1 of the earliest cholinesterase inhibitors to be studied, produced modest improvement in cognition in some patients by inhibiting intrasynaptic degradation of acetylcholine (06). Its use was limited because of the frequent dosing required and the severe adverse reactions it caused. In 1993, tacrine was the first cholinesterase inhibitor to be approved for use in Alzheimer disease, but it was discontinued because of its hepatotoxicity. In 1996, donepezil, a selective cholinesterase inhibitor, was approved for use in Alzheimer disease. In 2000, rivastigmine, a pseudoreversible cholinesterase inhibitor, was approved by the Food and Drug Administration, having been previously approved and used in several other countries. A transdermal preparation of rivastigmine was approved by the FDA in 2007.

This is an article preview.
Start a Free Account
to access the full version.

  • Nearly 3,000 illustrations, including video clips of neurologic disorders.

  • Every article is reviewed by our esteemed Editorial Board for accuracy and currency.

  • Full spectrum of neurology in 1,200 comprehensive articles.

  • Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660



ISSN: 2831-9125